<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02739035</url>
  </required_header>
  <id_info>
    <org_study_id>15-009075</org_study_id>
    <nct_id>NCT02739035</nct_id>
  </id_info>
  <brief_title>MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty</brief_title>
  <acronym>MUA</acronym>
  <official_title>Manipulation Under Anesthesia (MUA) to Treat Postoperative Stiffness After Total Knee Arthroplasty: A Multicenter Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Knee Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Compare the outcome following manipulation under anesthesia for stiffness in a randomized&#xD;
      controlled fashion with one group receiving IV dexamethasone and oral celecoxib at the time&#xD;
      of manipulation to a control group receiving manipulation alone.&#xD;
&#xD;
      Outcomes will include pain, range of motion, as well as subjective outcome scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stiffness is a potential complication following Total Knee Arthroplasty (TKA). While a&#xD;
      variety of factors have been cited as possible causes, such as component malrotation or&#xD;
      improper soft-tissue balancing, however, an etiology is not always appreciated. Histologic&#xD;
      and arthroscopic evidence of fibrosis suggests that an inflammatory process may contribute to&#xD;
      loss of knee range of motion following surgery. Manipulation under anesthesia remains&#xD;
      standard of care for stiffness following TKA. Manipulation shows improved range of motion for&#xD;
      stiffness after total knee arthroplasty, however, patients do not always achieve full range&#xD;
      of motion. Furthermore, repeat manipulation and manipulation greater than 8 weeks&#xD;
      post-surgically have shown limited improvements. Given a possible role of the host&#xD;
      inflammatory response and the importance of early gains in knee range of motion following&#xD;
      total knee arthroplasty, limiting the inflammatory response at the time of manipulation may&#xD;
      improve outcomes. Investigators would like to assess the role of anti-inflammatory&#xD;
      medications to optimize range of motion and outcome for manipulation under anesthesia for&#xD;
      stiffness following TKA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee range of motion after manipulation</measure>
    <time_frame>6 weeks after manipulation</time_frame>
    <description>Knee range of motion measures will include both passive and active flexion and extension</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee range of motion after Total Knee Arthroplasty</measure>
    <time_frame>1 year from the date of the Total Knee Arthroplasty</time_frame>
    <description>Knee range of motion measures will include both passive and active flexion and extension</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Society Scores</measure>
    <time_frame>Baseline, 6 weeks after the MUA, and 1 year after the TKA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-item Short Form Survey (SF-12)</measure>
    <time_frame>Baseline, 6 weeks after the MUA, and 1 year after the TKA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>Baseline, 6 weeks after the MUA, and 1 year after the TKA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Promise-29 outcome form</measure>
    <time_frame>Baseline, 6 weeks after the MUA, and 1 year after the TKA</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Stiffness Following Total Knee Arthroplasty</condition>
  <arm_group>
    <arm_group_label>MUA alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will be given manipulation under anesthesia, will fill out questionnaires about their knee and quality of life and will be followed throughout their routine follow up to assess their continued process. Subjects will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUA with dexamethasone and celecoxib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For subjects assigned to the MUA with anti-inflammatory medication group, an intravenous (into the vein) dose of dexamethasone will be given at the time of MUA. Subjects in this group will also receive celecoxib. They will be asked to take the medicine one time daily either at morning or night time with food and water for 2 weeks following MUA. Subjects will also be followed throughout their routine follow up to assess their continued process, and they will fill out questionnaires at the time of their consent and their 6-week and 1-year follow up visits. The questionnaires will take about 15-20 minutes to complete.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>8 mg of IV dexamethasone immediately before MUA.</description>
    <arm_group_label>MUA with dexamethasone and celecoxib</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>2 weeks per mouth of celecoxib (200 mg daily)</description>
    <arm_group_label>MUA with dexamethasone and celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who have received a primary unilateral TKA for a diagnosis of osteoarthritis.&#xD;
&#xD;
          2. MUA's scheduled between 6-10 weeks postoperatively&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Intolerance to NSAIDs&#xD;
&#xD;
          2. Renal dysfunction&#xD;
&#xD;
          3. Age &lt; 18 or &gt; 90 years&#xD;
&#xD;
          4. Primary diagnosis of rheumatoid arthritis&#xD;
&#xD;
          5. Patients with a Glomerular Filtration Rate (GFR) &lt;60 as the cut off for Chronic Kidney&#xD;
             Disease (CKD) (stage 3 CKD)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdel Matthew, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Cole</last_name>
    <phone>(507) 284-5445</phone>
    <email>cole.lauren@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>HipKnee Arkansas Foundation</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Wilson</last_name>
      <email>bwilson@hipkneearkansas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Joint Replacement</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aviva Pollet</last_name>
      <email>AvivaPollet@centura.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne DeBenedetti</last_name>
      <email>Anne.DeBenedetti@rushortho.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Cole</last_name>
      <phone>507-284-5445</phone>
      <email>ORCU@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Abdel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Danielson</last_name>
      <email>peter.danielson@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Waren</last_name>
      <email>Daniel.Waren@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Tam</last_name>
      <email>tamk@HSS.EDU</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York - Presbyterian at Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walkania Santos</last_name>
      <email>ws2590@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OrthoCarolina</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexis Ready</last_name>
      <email>Alexis.Ready@orthocarolina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Ceter, Dept. of Orthopaedics</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Friend</last_name>
      <email>jennifer.friend@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Klika</last_name>
      <email>klikaa@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joint Implant Surgeons</name>
      <address>
        <city>New Albany</city>
        <state>Ohio</state>
        <zip>43054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Sneller</last_name>
      <email>snellerma@joint-surgeons.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rothman Institute</name>
      <address>
        <city>Lansdale</city>
        <state>Pennsylvania</state>
        <zip>19446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mason Buccilla</last_name>
      <email>Mason.Buccilla@rothmanortho.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aria 3B Orthopaedic Specialists</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Anderson</last_name>
      <email>michelleanderson@ariahealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Houston Methodist</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Sullivan</last_name>
      <email>tsullivan@houstonmethodist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanna Lougmiller</last_name>
      <email>Shanna.Loughmiller@hsc.utah.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2016</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Matthew P. Abdel, M.D.</investigator_full_name>
    <investigator_title>Consultant - Knee Surgery</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

